Sentinel Lymph Node Mapping in Uterine-Confined Endometrial Cancer: ICG Protocol and Management
Direct Recommendation
For all patients with presumed uterus-confined endometrial cancer, perform sentinel lymph node (SLN) biopsy using indocyanine green (ICG) with cervical injection as the standard staging approach, apply ultrastaging to all retrieved SLNs, and perform side-specific systematic pelvic lymphadenectomy when mapping fails on either side in high-intermediate or high-risk patients 1, 2.
ICG Injection Technique
The FDA-approved dosing protocol is clear and specific 2:
- Dose: 5 mg total ICG administered as four 1 mL injections of a 1.25 mg/mL solution
- Injection sites: Cervix at 3 o'clock and 9 o'clock positions
- Superficial injection: 1-3 mm depth at each position
- Deep injection: 1-3 cm depth at each position
- Timing: Fluorescent lymphatic vessels and nodes become visible within 1 minute after injection
- Reconstitution: Dissolve 25 mg ICG powder with 20 mL sterile water to achieve 1.25 mg/mL concentration
The 2025 ESGO guidelines explicitly state that cervical injection with ICG is the preferred detection technique 1. This is supported by meta-analysis data showing cervical injection increases bilateral detection rates compared to alternative techniques, though it may decrease para-aortic detection 3.
Management of Mapping Failure
When to Perform Backup Lymphadenectomy
The 2025 ESGO guidelines provide a risk-stratified algorithm 1:
If SLNs are NOT detected on either pelvic side:
- High-intermediate or high-risk patients: Side-specific systematic pelvic lymphadenectomy is mandatory (Level II, A evidence)
- Intermediate-risk patients: Side-specific lymphadenectomy can be considered (weaker recommendation)
Tracer Re-injection Option
Tracer re-injection is an option if SLNs are not visualized upfront 1. Recent data suggest that optimized algorithms should also consider anatomic-based node removal: if mapping fails specifically in the proximal obturator or interiliac positions (the "typical positions"), remove nodes from those defined anatomic sites even if mapping occurred elsewhere, as isolated metastases occur in these locations in 4.3% of node-positive women with mapping failure 4.
Ultrastaging Protocol: Critical for Accuracy
What Ultrastaging Entails
All sentinel lymph nodes must undergo ultrastaging 1, 5. This intensive pathological assessment includes:
- Serial sectioning with multiple levels examined
- Initial section followed by at least 2 additional levels spaced 50-250 microns apart 1
- H&E staining combined with cytokeratin immunohistochemistry 5
The 2025 ESGO guidelines acknowledge that pathologists have not reached consensus on the exact number of sectioning levels, but the minimum standard is clear 1.
Why Ultrastaging Matters
Ultrastaging detects metastases that would be missed by conventional single-section H&E staining:
- Upstaging occurs in 5-15% of patients through ultrastaging 5
- In one cohort of 508 patients, ultrastaging detected 23 additional micrometastases that standard H&E would have missed 5
- A multicenter study showed SLN biopsy with ultrastaging detected metastatic nodes in 3-fold more patients than standard lymphadenectomy 5
- The negative predictive value and sensitivity approach 100% when ultrastaging is properly applied 6, 7
Management of Low-Volume Metastases
When ultrastaging detects isolated tumor cells (ITCs) without macrometastasis or micrometastasis:
- Lymph node stage is designated as pN0(i+) per AJCC 8th edition 5
- ITCs should be clearly reported even though they don't affect overall staging 5
- The clinical significance remains under investigation, but most patients with ITCs receive adjuvant chemotherapy (83% in one series) 5
Performance Metrics and Practical Considerations
Expected Detection Rates
Based on the most comprehensive meta-analysis 3 and recent institutional series:
- Overall detection rate: 81% (any SLN detected) 3
- Bilateral pelvic detection: 50-79% 3, 8
- Para-aortic detection: 17% 3
- Sensitivity for metastases: 96% (95% CI: 91-98%) 3
Recent single-center studies using optimized protocols report even higher success: 93.9% overall mapping success and 95.9% detection rate 9, with some centers achieving 100% detection 6.
Factors Affecting Success
ICG is superior to blue dye: Bilateral detection rates are significantly higher with ICG versus patent blue (79.2% vs 27.3%, p<0.001) 9.
Surgical platform: Both conventional laparoscopy and robotic surgery achieve comparable SLN mapping success (90.3% vs 91.6%, p=1.000) 8. The choice of minimally invasive platform does not significantly impact detection rates.
Patient factors: Detection rates are not significantly affected by BMI, tumor histology, or tumor grade 3, 10, though obesity may increase complication rates from subsequent lymphadenectomy 10.
Application to High-Risk Histologies
SLN mapping is appropriate for high-risk histologies (serous, clear cell, carcinosarcoma, grade 3) 1, 5. The SENTOR trial demonstrated 96% sensitivity (95% CI: 81-100%) for SLN mapping in intermediate- and high-grade endometrial cancer 5. Multiple studies confirm that SLN mapping versus complete lymphadenectomy does not impact survival outcomes in high-risk disease 5.
For serous carcinoma, carcinosarcoma, and undifferentiated carcinoma at clinical stage I-II, add infracolic omentectomy to the surgical procedure 1.
Common Pitfalls to Avoid
Failing to perform ultrastaging: Standard single-section pathology will miss 5-15% of metastases 5
Not performing backup lymphadenectomy in high-risk patients with mapping failure: This is a mandatory step, not optional 1
Using blue dye instead of ICG: ICG provides significantly superior bilateral detection 9, 3
Abandoning the procedure in obese patients: Detection rates remain acceptable across BMI categories 3, 10
Assuming mapping failure means no metastases: Always perform side-specific lymphadenectomy when mapping fails, particularly removing nodes from typical anatomic positions (obturator, interiliac) 1, 4
Not considering tracer re-injection: This simple maneuver can salvage failed initial mapping 1